Anúncio
Anúncio
KYMR
Kymera Therapeutics, Inc. Common Stock
72.72
USDPatrocinado
-5.09
-6.55%
02 de jan., 15:59 UTC -5
Encerrado
Pós-Mercado
72.61
-0.10
-0.14%
Relatórios de Lucros KYMR
Rácio de surpresa positiva
KYMR separação 6 de 21 últimas estimativas.
29%
Próximo Relatório
Data do Próximo Relatório
25 de fev. de 2026
Estimate for Q4 25 (Revenue/ EPS)
$15.47M
/-$0.81
Mudanças implicadas de Q3 25 (Revenue/ EPS)
+459.71%
/-13.83%
Mudanças implicadas de Q4 24 (Revenue/ EPS)
+109.23%
/-7.95%
Kymera Therapeutics, Inc. Common Stock earnings per share and revenue
On 04 de nov. de 2025, KYMR reported earnings of -0.94 USD per share (EPS) for Q3 25, missing the estimate of -0.82 USD, resulting in a -14.63% surprise. Revenue reached 2.76 milhão, compared to an expected 19.33 milhão, with a -85.70% difference. The market reacted with a +0.32% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 25 analistas forecast an EPS of -0.81 USD, with revenue projected to reach 15.47 milhão USD, implying an diminuir of -13.83% EPS, and aumentar of 459.71% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
enGene Holdings Inc. Common Stock
Report Date
22 de dez. de 2025 Para Q4 25
Estimativa
-$0.57
Real
-$0.73
Surpresa
-25.95%
Outlook Therapeutics, Inc. Common Stock
Report Date
19 de dez. de 2025 Para Q4 25
Estimativa
-$0.25
Real
-$0.19
Surpresa
+26.47%
Citius Oncology, Inc. Common Stock
Report Date
23 de dez. de 2025 Para Q4 25
Estimativa
-$0.12
Real
-$0.06
Surpresa
+50.98%
FAQ
What were Kymera Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Kymera Therapeutics, Inc. Common Stock reported EPS of -$0.94, missing estimates by -14.63%, and revenue of $2.76M, -85.7% below expectations.
How did the market react to Kymera Therapeutics, Inc. Common Stock's Q3 2025 earnings?
The stock price moved up 0.32%, changed from $59.72 before the earnings release to $59.91 the day after.
When is Kymera Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for 25 de fev. de 2026.
What are the forecasts for Kymera Therapeutics, Inc. Common Stock's next earnings report?
Based on 25
analistas, Kymera Therapeutics, Inc. Common Stock is expected to report EPS of -$0.81 and revenue of $15.47M for Q4 2025.
Which companies are reporting earnings today?
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio